Abstract 6002
Background
Although cancer patients are known to be at higher risk of infection and its subsequent complications, the magnitude of infection-related mortality in cancer patients remains unknown. In this study, data from Surveillance, Epidemiology, and End Results Program (SEER) were explored in order to identify how far infection was identified as the cause of death in cancer patients in the United States between 2010 and 2016.
Methods
Data were obtained using SEER*Stat version 8.3.5 where (SEER 18 Regs Nov 2018 Submission) was used as the data source. Only cases with malignant behavior, known age, and those in research database were included. Analysis was made for patients who were diagnosed between 2010 and 2016 whose vital status was reported as "dead" at the time of study cut-off. Data about cause of death were exported using case-listing session in SEER*Stat and were analyzed using SPSS version 25.
Results
1,012,769 cases were included in the final data analysis. Infection was identified as the cause of death in 1.89% of cases (n = 19,155). Infection-related mortality was much higher in patients diagnosed with hematological malignancies (3.6%, n = 3,472) compared with non-hematological malignant diseases (1.7%, n = 15683). Deaths related to infection were also higher in males (2.2%, n = 11,827) compared with females (1.6%, n = 7,328).
Conclusions
Although infection is perceived as a major cause of morbidity and mortality in cancer patients, its current magnitude may be lower than expectations. Infection-related mortality showed higher prevelance in males and in patients with hematological malignancies.
Clinical trial identification
N/A
Editorial acknowledgement
N/A
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4085 - A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-601 in Patients with Advanced Solid Tumors
Presenter: Anthony Tolcher
Session: Poster Display session 1
Resources:
Abstract
1054 - Safety, efficacy, and pharmacokinetic (PK) profile of cosibelimab, an anti‐PD‐L1 antibody, in patients (pts) with advanced cancers
Presenter: Philip Clingan
Session: Poster Display session 1
Resources:
Abstract
4264 - A Phase I study of tinostamustine in patients (pts) with advanced solid tumours
Presenter: Alain Mita
Session: Poster Display session 1
Resources:
Abstract
3811 - Lurbinectedin (LUR) in combination with Irinotecan (IRI) in patients (pts) with advanced solid tumors
Presenter: Santiago Ponce Aix
Session: Poster Display session 1
Resources:
Abstract
1311 - A phase I study of varlitinib (VAR; ASLAN001) an oral pan-HER tyrosine kinase inhibitor (TKI) combined with mFOLFIRI chemotherapy in advanced solid tumors
Presenter: Aaron Tan
Session: Poster Display session 1
Resources:
Abstract
3482 - Phase I study of lapatinib and trametinib in patients with KRAS mutant colorectal, non-small cell lung and pancreatic cancer
Presenter: Sanne Huijberts
Session: Poster Display session 1
Resources:
Abstract
4749 - Pharmacokinetic (PK) and updated survival data from the Canadian Cancer Trials Group IND.226 study of durvalumab ± tremelimumab in combination with platinum-doublet chemotherapy
Presenter: Desiree Hao
Session: Poster Display session 1
Resources:
Abstract
4530 - A Phase 2a clinical trial combining ALRN-6924 and palbociclib for the treatment of patients with tumors harboring wild-type p53 and MDM2 amplification or MDM2/CDK4 co-amplification
Presenter: Funda Meric-Bernstam
Session: Poster Display session 1
Resources:
Abstract
4280 - Updated Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Tumors: Integrated Analysis of STARTRK-2, STARTRK-1 and ALKA-372-001
Presenter: Christian Rolfo
Session: Poster Display session 1
Resources:
Abstract
6144 - An international randomized cross-over bio-equivalence study of oral paclitaxel + HM30181 compared with weekly intravenous (IV) paclitaxel in patients with advanced solid tumors
Presenter: Christopher Jackson
Session: Poster Display session 1
Resources:
Abstract